The first compulsory licence has been granted by the Controller of Patents Mumbai.

The application concerns the anti-cancer drug Sorafenib, a patented drug owned by Bayer Corporation. The applicant for a compulsory licence is Natco Pharma Limited, an Indian generic pharmaceuticals company.

Darren Smyth's post on the IPKat explores the implications of this landmark decision.